We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The U.S. Food and Drug Administration (FDA) has approved changes to the hydrochlorothiazide (HCTZ) drug label to inform health care professionals and patients about a small increased risk of non-melanoma skin cancer (basal cell skin cancer or squamous ...